Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome - 18/07/13
Abstract |
Assays monitoring P2Y12 platelet reactivity can accurately predict which patients will have a poor response to clopidogrel. We sought to determine the cost-effectiveness of using platelet reactivity assays (PRAs) to select a dual-antiplatelet regimen for patients with acute coronary syndrome. A hybrid decision tree Markov model was developed to determine the cost-effectiveness of universal clopidogrel, ticagrelor, or prasugrel (given to all patients) or PRA-driven ticagrelor or prasugrel (given to patients with high platelet reactivity, defined as >230 on the VerifyNow P2Y12 assay; the others received generic clopidogrel). We assumed a cohort of 65-year-old patients with acute coronary syndrome and an incidence of high platelet reactivity of 32% and 13% at ∼24 to 48 hours after revascularization and 1 month, respectively. The 5-year costs, quality-adjusted life-years, and incremental cost-effectiveness ratios were calculated for PRA-driven ticagrelor and prasugrel compared with universal clopidogrel, ticagrelor, or prasugrel. PRA-driven ticagrelor and prasugrel were cost-effective compared with universal clopidogrel (incremental cost-effectiveness ratio $40,100 and $49,143/quality-adjusted life-year, respectively); however, universal ticagrelor and prasugrel were not (incremental cost-effectiveness ratio $61,651 and $96,261/quality-adjusted life-year, respectively). Monte Carlo simulation suggested PRA-driven ticagrelor, PRA-driven prasugrel, universal ticagrelor, and universal prasugrel would have an incremental cost-effectiveness ratio <$50,000/quality-adjusted life-year in 52%, 40%, 23%, and 2% of the iterations compared with universal clopidogrel, respectively. Universal ticagrelor and prasugrel were not cost-effective compared with their respective PRA-driven regimens (incremental cost-effectiveness ratio $68,182; $116,875/quality-adjusted life-year, respectively). Monte Carlo simulation suggested universal ticagrelor and prasugrel would have an incremental cost-effectiveness ratio <$50,000/quality-adjusted life-year in 26% and 4% of iterations compared with their respective PRA-driven regimens. The results were most sensitive to differences in agent costs and drug-specific relative risks of death. In conclusion, even with generic clopidogrel, PRA-driven selection of antiplatelet therapy appeared to be a cost-effective strategy with the potential to decrease the overall acute coronary syndrome-associated healthcare costs.
Le texte complet de cet article est disponible en PDF.Plan
| This research was supported by Accumetrics, Inc. (San Diego, California). |
|
| The authors maintained full control over the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the report. Accumetrics, Inc. (San Diego, California) reviewed the final manuscript before submission. Drs. Coleman and Limone had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. |
|
| See page 361 for disclosure information. |
Vol 112 - N° 3
P. 355-362 - août 2013 Retour au numéro
Article précédent
- Comparative Analysis of Cardiovascular Disease Risk Factors Influencing Nonfatal Acute Coronary Syndrome and Ischemic Stroke
- Christina-Maria Kastorini, Ekavi Georgousopoulou, Konstantinos N. Vemmos, Vassilios Nikolaou, Dimitrios Kantas, Haralampos J. Milionis, John A. Goudevenos, Demosthenes B. Panagiotakos
- Impact of Angiotensin II Receptor Blocker Therapy (Olmesartan or Valsartan) on Coronary Atherosclerotic Plaque Volume Measured by Intravascular Ultrasound in Patients With Stable Angina Pectoris
- Hideki Ishii, Masakazu Kobayashi, Nobutake Kurebayashi, Daiji Yoshikawa, Susumu Suzuki, Satoshi Ichimiya, Masaaki Kanashiro, Takahito Sone, Hideyuki Tsuboi, Tetsuya Amano, Tadayuki Uetani, Ken Harada, Nobuyuki Marui, Toyoaki Murohara
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?